Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yu Jung | - |
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Hyun, Hakjun | - |
dc.contributor.author | Nham, Eliel | - |
dc.contributor.author | Yoon, Jin Gu | - |
dc.contributor.author | Seong, Hye | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.date.accessioned | 2022-11-18T08:40:27Z | - |
dc.date.available | 2022-11-18T08:40:27Z | - |
dc.date.created | 2022-11-17 | - |
dc.date.issued | 2022-09-23 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/145735 | - |
dc.description.abstract | Although some studies have reported prognostic factors for coronavirus disease 2019 (COVID-19), they were conducted before standard treatment with remdesivir and dexamethasone was implemented. This retrospective, observational study was conducted to evaluate various prognostic factors in patients with COVID-19 pneumonia receiving standard treatment with remdesivir and dexamethasone. Of 99 patients with COVID-19 pneumonia, 68 (68.7%) died within 30 days of hospitalization. The mean age was 71.3 years. Remdesivir and dexamethasone were administered to 80 (80.8%) and 84 (84.8%) patients, respectively. Early antibiotic treatment was administered to 70 patients (70.7%) within 5 days of hospitalization. Dexamethasone (79.4% vs 96.8%, P = .033) was more frequently administered in the survived group, whereas early antibiotics (60.3% vs 93.5%, P = .001) were less frequently administered. In the multivariate analysis, a high National Early Warning Score (NEWS; odds ratio [OR] 1.272), high Charlson Comorbidity Index (CCI; OR 1.441), and dyspnea (OR 4.033) were independent risk factors for 30-day mortality. There was no significant difference in age, sex, and vaccination doses between the survived and fatal groups. Lymphopenia, monocytopenia and high levels of C-reactive protein (CRP)/lactate dehydrogenase (LDH) reflected poor prognosis. NEWS, CCI, and dyspnea were predictors of 30-day mortality in patients with COVID-19 pneumonia. Early antibiotic use did not lower the 30-day mortality risk. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | CELL DISTRIBUTION WIDTH | - |
dc.subject | C-REACTIVE PROTEIN | - |
dc.subject | RISK | - |
dc.title | Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Joon Young | - |
dc.contributor.affiliatedAuthor | Yoon, Jin Gu | - |
dc.contributor.affiliatedAuthor | Noh, Ji Yun | - |
dc.identifier.doi | 10.1097/MD.0000000000030474 | - |
dc.identifier.scopusid | 2-s2.0-85139191950 | - |
dc.identifier.wosid | 000857180100061 | - |
dc.identifier.bibliographicCitation | MEDICINE, v.101, no.38, pp.E30474 | - |
dc.relation.isPartOf | MEDICINE | - |
dc.citation.title | MEDICINE | - |
dc.citation.volume | 101 | - |
dc.citation.number | 38 | - |
dc.citation.startPage | E30474 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | CELL DISTRIBUTION WIDTH | - |
dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | mortality | - |
dc.subject.keywordAuthor | pneumonia | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.